However, CD19+CD38highIgM+ transitional B cells were significantly higher in COVID‐19 convalescent patients when compared to healthy control subjects (5.00 ± 3.07% vs 3.57  ± 2.30%; P = .0020) (Figure 3; Figures S6, S7 and Table S5). The gene discussed is CD19; the disease is COVID-19.